- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2402EUR$2,750USD£2,086GBP
- Report
- January 2022
- 200 Pages
Global
From €6550EUR$7,500USD£5,690GBP
- Report
- January 2022
- 60 Pages
Global
From €3450EUR$3,950USD£2,997GBP
- Report
- May 2024
- 200 Pages
Global
From €3624EUR$4,150USD£3,148GBP
- Report
- May 2024
- 133 Pages
Global
From €5676EUR$6,499USD£4,931GBP
- Report
- September 2024
- 82 Pages
Japan
From €3057EUR$3,500USD£2,655GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4323EUR$4,950USD£3,755GBP
- Report
- August 2022
- 118 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- March 2023
- 75 Pages
Spain
From €2340EUR$2,680USD£2,033GBP
€2926EUR$3,350USD£2,542GBP
- Report
- October 2022
- 80 Pages
Europe
From €2620EUR$3,000USD£2,276GBP
€3275EUR$3,750USD£2,845GBP
- Report
- September 2022
- 82 Pages
Turkey
From €2340EUR$2,680USD£2,033GBP
€2926EUR$3,350USD£2,542GBP
- Report
- July 2024
- 185 Pages
Global
From €2183EUR$2,500USD£1,897GBP
- Report
- October 2023
- 162 Pages
Global
From €2183EUR$2,500USD£1,897GBP
- Drug Pipelines
- July 2020
- 1191 Pages
Global
From €2183EUR$2,500USD£1,897GBP
- Report
- March 2024
- 221 Pages
Global
From €3144EUR$3,600USD£2,731GBP
- Report
- March 2024
- 121 Pages
Europe
From €1310EUR$1,500USD£1,138GBP
- Report
- March 2024
- 122 Pages
Asia Pacific
From €1310EUR$1,500USD£1,138GBP
- Report
- March 2024
- 112 Pages
North America
From €1310EUR$1,500USD£1,138GBP
- Report
- March 2024
- 121 Pages
Middle East, Africa
From €1310EUR$1,500USD£1,138GBP
- Report
- November 2020
- 46 Pages
Global
From €3489EUR$3,995USD£3,031GBP

The Rheumatoid Arthritis Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat rheumatoid arthritis, an autoimmune disorder that causes inflammation of the joints. These drugs are used to reduce inflammation, pain, and stiffness, as well as to prevent joint damage. They can be divided into two categories: disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (BRMs). DMARDs are used to slow the progression of the disease, while BRMs are used to reduce inflammation and pain.
The Rheumatoid Arthritis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more